New! Sign up for our free email newsletter.
Science News
from research organizations

Potential for more targeted treatments of neuroblastoma tumors

Date:
June 19, 2017
Source:
University of Chicago Medical Center
Summary:
Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.
Share:
FULL STORY

Genetic variations appear to pre-dispose children to developing certain severe forms of neuroblastoma, according to new research by the University of Chicago Medicine. The findings lay the groundwork for developing more targeted treatments for particularly deadly variations of the cancer.

Neuroblastoma affects about 1,000 children in the United States per year. Patients are placed into different risk categories for their disease. Each risk category determines the intensity of the treatment regimen and likelihood of a patient's survival. Children in lower-risk categories experience a roughly 95 percent survival rate with minimal treatment. But, if a child is classified as high-risk, the survival rate falls to approximately 50 percent even with an aggressive treatment plan that includes high-dose chemotherapy, surgery, stem cell transplant, radiation and immunotherapy. One common indicator of high-risk cancer is if a child has extra copies (amplification) of a gene called MYCN (pronounced mick-N).

The findings, published in the Journal of the National Cancer Institute, are the first to look at genetic predispositions of why some children develop MYCN-amplified neuroblastoma tumors and others develop non-MYCN-amplified tumors.

"If we can understand the genetic events causing the development of these different types of tumors, we can point away from certain types of treatments and refine the therapies we recommend," said Mark Applebaum, MD, assistant professor of pediatrics at the University of Chicago Medicine.

Applebaum and his team analyzed baseline genetic characteristics of about 3,200 neuroblastoma patients around the country. The team studied the patients' inheritable genetics and associated them to the type of neuroblastoma they developed. The results showed that common genetic variations in patients predisposed them to developing different neuroblastoma genotypes, including the likelihood of developing MYCN-amplification.

"Associating patient genetics with tumor genotype is a relatively new idea," said Applebaum. "We tried to link germline characteristics with MYCN-amplified versus non-MYCN-amplified tumors."

Further studies are needed to build on the research and eventually develop targeted treatment regimens for children with varying high-risk neuroblastoma tumors.


Story Source:

Materials provided by University of Chicago Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. Eric A. Hungate, Mark A. Applebaum, Andrew D. Skol, Zalman Vaksman, Maura Diamond, Lee McDaniel, Samuel L. Volchenboum, Barbara E. Stranger, John M. Maris, Sharon J. Diskin, Kenan Onel, Susan L. Cohn. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. JNCI: Journal of the National Cancer Institute, 2017; 109 (10) DOI: 10.1093/jnci/djx093

Cite This Page:

University of Chicago Medical Center. "Potential for more targeted treatments of neuroblastoma tumors." ScienceDaily. ScienceDaily, 19 June 2017. <www.sciencedaily.com/releases/2017/06/170619125842.htm>.
University of Chicago Medical Center. (2017, June 19). Potential for more targeted treatments of neuroblastoma tumors. ScienceDaily. Retrieved March 28, 2024 from www.sciencedaily.com/releases/2017/06/170619125842.htm
University of Chicago Medical Center. "Potential for more targeted treatments of neuroblastoma tumors." ScienceDaily. www.sciencedaily.com/releases/2017/06/170619125842.htm (accessed March 28, 2024).

Explore More

from ScienceDaily

RELATED STORIES